logo
Lithium might be back but the ride will be wild

Lithium might be back but the ride will be wild

News.com.au5 days ago
There's been some violent gyrations in lithium markets over the past couple of weeks but sentiment appears to be turning.
Liontown Resources (ASX:LTR) managing director Tony Ottaviano pointed out on Tuesday that spodumene futures had surged by US$60 per tonne on Friday but then dropped by US$50/t on Monday.
'Notwithstanding that, we've seen some green shoots in the past two weeks,' he said.
Pilbara Minerals (ASX:PLS) managing director Dale Henderson is cautiously optimistic.
'There are signs the lithium winter may be lifting, but it's early in this change,' he said yesterday.
'The lithium market has long been marked by volatility, with prices prone to sharp and sometimes counterintuitive swings.
'The volatility is not incidental. It reflects a still nascent market with limited liquidity, few futures mechanisms and undeveloped trading infrastructure. Pricing remains inefficient.
'In this environment, short term moves are often driven by sentiment, policy signals or speculative flows, rather than durable shifts in supply and demand.'
Henderson pointed that the price had sunk to levels over the past year that made much of the global lithium sector unprofitable.
'This was not the result of a fundamental oversupply alone, but an immature market that remains in development,' he said.
'The recent price rally, which began late in the June quarter and accelerated into July, follows this pattern, a sentiment-led rebound triggered by perceived supply risks.
'In this case, Chinese regulatory reviews of brine and lepidolite operations and the suspension of a major project fuelled renewed price momentum.'
According to reports, eight lithium mines in Jiangxi are being scrutinised, which could potentially lead to suspensions.
Shanghai Metals Market's baseline forecast for August was a 300 tonne surplus, but it suggested even limited disruptions could reduce monthly supply by 2000-2500t.
In the case of moderate disruption, meaning a temporary suspension of Jiangxi mines, the impact would be 8000-10,000t in August, easing to 5000t a month by the December quarter.
If mines are completely shut down, it forecasts a 10,000t impact to supply in August, escalating to 14,000t a month by the end of the year.
'Now, we remain cautiously optimistic but continue to monitor whether the flagged supply side adjustments will eventuate,' Henderson said.
Picking the bottom
Joe Lowry, the US-based founder of advisory Global Lithium, believes the lithium winter has ended.
'I believe the market has bottomed and we've started the next cycle,' he said in a video posted to X.
IGO boss Ivan Vella yesterday seemed less convinced, commenting on the unseasonably cold winter in Perth this year and comparing it to the lithium winter.
'I suspect it'll warm up in Perth a lot before we see a real shift in the lithium market,' he said.
Henderson cautioned it was a partial correction at this stage and not yet a full recovery and prices still remained well below the levels needed to incentivise new production.
'While near-term pricing is volatile, the long-term demand picture remains robust and continues to strengthen,' he said.
He said global electric vehicle sales reached five million units in the June quarter, up 27% year-on-year, while EV penetration hit 50% in China in June and 25% for the rest of the world.
Energy storage system demand is also building.
'Forecasts indicate 40% year-on-year growth for ESS in this calendar year alone,' Henderson said.
'Together, EVs and ESS are expected to account for something like 90% of lithium demand by 2030, highlighting a powerful and durable and structural demand trend.'
Late last week, Canaccord Genuity analysts conceded that demand was much stronger than it expected and low pricing had hollowed out future supply growth.
'As demand growth overtakes supply growth, we see a much tighter market and potential for continued pricing improvements,' the firm's research team, led by Reg Spencer, said.
'There still appears to be oversupply today, but we think demand growth is rapidly eating into this. By 2027, additional will supply be needed and in the absence of higher incentive levels, this could elicit a more dramatic pricing response.
'We think the down cycle in the sector has now likely passed and see lithium equities as set to benefit.'
What about juniors?
The renewed optimism has flowed down into the junior space.
Explorer Perpetual Resources (ASX:PEC) has more than doubled this month after completing the maiden drill program at its Igrejinha project in Brazil's 'Lithium Valley', which is also home to PLS' advanced Colinas development project.
Canadian players Patriot Battery Metals (ASX:PMT) and Green Technology Metals (ASX:GT1) have surged, with each adding critical minerals components to their lithium resources.
Western Australian junior Global Lithium Resources (ASX:GL1) is up by more than 45% over the past month, while fellow WA explorer Delta Lithium (ASX:DLI) is up by more than 25% over the same period.
Argentina-focused Pursuit Minerals (ASX:PUR) is up 24% this month and managing director Aaron Revelle last week told Stockhead he could feel the change in sentiment on the ground.
'There's more inbound interest, especially those looking to secure supply outside of China,' he said.
'Juniors with pilot scale production, strong grades, and a clear pathway to development are getting a second look. It's cautious optimism, but the tone has improved from earlier this year.'
Astute Metals (ASX:ASE) is taking advantage of the 20% rise in its share price over the past few days to raise fresh capital to continue advancing its Red Mountain lithium project in Nevada.
It comes after the company reported high-grade hits of 62.4m at 1210 parts per million lithium from 152.2m, including 27m at 1420ppm lithium and 33.8m at 1130ppm lithium from 34.8m, including 10.7m at 1320ppm lithium on Friday.
The results will underpin an initial resource estimate to be reported by the end of the year.
Meanwhile, Chariot Corporation (ASX:CC9) is positioning itself for the recovery and China's strong demand by picking up new ground.
Earlier this month, the company picked up the largest portfolio of lithium assets in Nigeria, which managing director Shanthar Pathmanathan described as a global lithium hot spot.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month
ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month

News.com.au

time29 minutes ago

  • News.com.au

ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of FebriDX in US subject to CLIA waiver Clever Culture Systems rose 81.3% in July on news global pharmaceutical giant Novo Nordisk purchased one of its flagship APAS Independence instruments for evaluation The healthcare sector rose 9.05% in July to be the best of the 11 ASX sectors. A turn up for the books to be sure. While remaining the worst performing sector YTD – up just 1.81% – the S&P ASX Health Care index was in recovery mode in July. The sector was buoyed by a roughly 13% rise in its biggest name blood products giant CSL (ASX:CSL), which drives much of the index. Morgans' healthcare analyst Iain Wilkie said there appeared to be a strong sector rotation on the ASX in July. "During July there certainly was a rotation out of usual strong sectors like financials and more into healthcare and the miners," he told Stockhead. "Healthcare has been beaten down for quite a long while now and is starting to look attractive. "I don't think there was anything specific in terms of a catalyst to drive the rotation." Looking ahead, Wilkie noted the sector may face continued pressure with US President Donald Trump again threatening tariffs " at a very, very, high rate, like 200%" on imported pharmaceuticals. "Trump has again thrown his weight around but until it actually hits we'll see," Wilkie said. He said US tariffs shouldn't affect companies like CSL, which is one of the world's largest manufacturers of plasma products. "Although the US collects over 60% of the world's plasma, it lacks sufficient domestic capacity to process it into finished therapies," he said. "As a result, imported plasma products are critical to meeting national demand. "Introducing tariffs on these products would likely be counterproductive as they wouldn't foster viable domestic alternatives and could drive up costs, potentially limiting patient access and causing harm." How ASX biotechs performed in July CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP PAB Patrys Limited $ 0.002 181.8% 6.9 LDX Lumos Diagnostics $ 0.073 170.4% 55.4 NSB Neuroscientific $ 0.235 170.1% 79.8 NXS Next Science Limited $ 0.140 109.0% 41.7 NOX Noxopharm Limited $ 0.110 103.7% 30.7 CMB Cambium Bio Limited $ 0.425 102.4% 8.2 DVL Dorsavi Ltd $ 0.028 86.7% 27.3 ICR Intelicare Holdings $ 0.013 85.7% 6.3 CC5 Clever Culture $ 0.029 81.3% 56.9 EMD Emyria Limited $ 0.049 75.0% 28.1 CU6 Clarity Pharma $ 4.370 74.8% 1,471.5 HMD Heramed Limited $ 0.012 71.4% 10.5 MX1 Micro-X Limited $ 0.083 69.4% 54.0 TTX Tetratherix Limited $ 5.020 66.2% 131.7 CAN Cann Group Ltd $ 0.016 60.0% 9.8 NYR Nyrada Inc. $ 0.370 54.2% 77.8 VBS Vectus Biosystems $ 0.06 50.0% 3.2 CSX Cleanspace Holdings $ 0.760 46.2% 59.5 MSB Mesoblast Limited $ 2.380 43.8% 3,046.3 AVE Avecho Biotech Ltd $ 0.005 42.9% 15.9 HIQ Hitiq Limited $ 0.020 42.9% 9.9 AYA Artryalimited $ 1.025 42.4% 116.7 ANR Anatara Ls Ltd $ 0.007 40.0% 1.5 ATH Alterity Therap Ltd $ 0.014 40.0% 128.9 CBL Control Bionics $ 0.040 37.9% 12.1 EYE Nova EYE Medical Ltd $ 0.150 36.4% 41.2 IBX Imagion Biosys Ltd $ 0.015 36.4% 3.0 IPD Impedimed Limited $ 0.047 34.3% 93.4 RCE Recce Pharmaceutical $ 0.388 33.6% 108.4 NTI Neurotech Intl $ 0.020 33.3% 21.0 VFX Visionflex Group Ltd $ 0.00 33.3% 6.7 AT1 Atomo Diagnostics $ 0.018 28.6% 14.2 AHC Austco Healthcare $ 0.370 27.6% 137.0 TRP Tissue Repair $ 0.240 26.3% 14.5 SOM SomnoMed Limited $ 0.815 25.4% 171.8 1AD Adalta Limited $ 0.003 25.0% 2.8 ADR Adherium Ltd $ 0.005 25.0% 9.0 BIT Biotron Limited $ 0.003 25.0% 3.3 CUV Clinuvel Pharmaceut. $ 12.970 25.0% 617.5 FRE Firebrickpharma $ 0.077 24.2% 17.5 CMP Compumedics Limited $ 0.315 23.5% 66.3 NEU Neuren Pharmaceut. $ 17.290 22.5% 2,150.6 ILA Island Pharma $ 0.170 21.4% 40.8 ATX Amplia Therapeutics $ 0.240 20.0% 111.9 DOC Doctor Care Anywhere $ 0.125 19.0% 47.7 EBR EBR Systems $ 1.410 18.0% 514.6 LTP Ltr Pharma Limited $ 0.340 17.2% 60.6 PAR Paradigm Bio. $ 0.355 16.4% 136.1 LGP Little Green Pharma $ 0.115 16.2% 35.1 M7T Mach7 Tech Limited $ 0.380 15.2% 89.3 ALC Alcidion Group Ltd $ 0.115 15.0% 154.4 NC6 Nanollose Limited $ 0.077 14.9% 24.1 CYC Cyclopharm Limited $ 1.040 14.3% 113.4 SPL Starpharma Holdings $ 0.100 13.6% 43.9 MVF Monash IVF Group Ltd $ 0.800 13.5% 309.8 SNT Syntara Limited $ 0.060 13.2% 97.6 CSL CSL Limited $ 270.900 13.1% 128,514.7 PME Pro Medicus Limited $ 321.890 12.9% 33,058.3 CVB Curvebeam Ai Limited $ 0.080 12.7% 33.2 IMM Immutep Ltd $ 0.270 12.5% 385.3 MVP Medical Developments $ 0.610 11.9% 64.8 TRJ Trajan Group Holding $ 0.800 11.9% 121.9 GLH Global Health Ltd $ 0.076 11.8% 4.5 VIT Vitura Health Ltd $ 0.07 11.3% 47.0 PIQ Proteomics Int Lab $ 0.360 10.8% 57.3 IRX Inhalerx Limited $ 0.042 10.5% 9.0 IDT IDT Australia Ltd $ 0.098 10.1% 40.7 NUZ Neurizon Therapeutic $ 0.170 9.7% 81.2 PGC Paragon Care Limited $ 0.400 9.6% 653.8 RHY Rhythm Biosciences $ 0.059 9.3% 17.4 1AI Algorae Pharma $ 0.006 9.1% 10.1 CTQ Careteq Limited $ 0.012 9.1% 2.8 AHX Apiam Animal Health $ 0.565 8.7% 103.0 ARX Aroa Biosurgery $ 0.630 8.6% 224.3 OCC Orthocell Limited $ 1.275 8.5% 309.7 MAP Microbalifesciences $ 0.092 8.2% 47.4 PSQ Pacific Smiles Grp $ 1.670 8.1% 269.9 PNV Polynovo Limited $ 1.290 7.9% 858.4 RMD ResMed Inc. $ 42.450 7.9% 61,930.3 PTX Prescient Ltd $ 0.047 6.8% 38.7 REG Regis Healthcare Ltd $ 8.370 6.8% 2,545.6 TYP Tryptamine Ltd $ 0.03 6.7% 44.6 SDI SDI Limited $ 0.883 6.3% 104.6 COH Cochlear Limited $ 318.520 6.0% 20,541.2 RHC Ramsay Health Care $ 38.770 5.7% 8,808.5 IDX Integral Diagnostics $ 2.670 5.1% 1,001.8 IMC Immuron Limited $ 0.064 4.9% 16.9 OCA Oceania Healthc Ltd $ 0.660 4.8% 461.5 EBO Ebos Group Ltd $ 37.250 4.7% 7,552.6 RAD Radiopharm $ 0.023 4.5% 54.4 ACW Actinogen Medical $ 0.024 4.3% 76.3 IIQ Inoviq Ltd $ 0.385 4.1% 43.5 AGH Althea Group $ 0.026 4.0% 21.4 IME Imexhs Limited $ 0.300 3.4% 15.8 CYP Cynata Therapeutics $ 0.155 3.3% 37.3 SHL Sonic Healthcare $ 27.610 3.1% 13,532.2 FPH Fisher & Paykel H. $ 34.090 1.4% 19,481.0 CTE Cryosite Limited $ 0.750 0.7% 36.6 VLS Vita Life Sciences.. $ 2.26 0.4% 124.4 ACR Acrux Limited $ 0.016 0.0% 7.0 BP8 Bph Global Ltd $ 0.002 0.0% 2.1 EMV Emvision Medical $ 1.740 0.0% 150.1 EOF Ecofibre Limited $ 0.020 0.0% 7.6 EPN Epsilon Healthcare $ 0.024 0.0% 7.2 NAN Nanosonics Limited $ 4.050 0.0% 1,196.3 OSX Osteopore Limited $ 0.011 0.0% 2.6 TD1 Tali Digital Limited $ 0.001 0.0% 4.2 TRI Trivarx Ltd $ 0.008 0.0% 5.0 TRU Truscreen $ 0.016 0.0% 12.3 ACL Au Clinical Labs $ 2.760 -0.7% 536.1 CGS Cogstate Ltd $ 1.730 -0.9% 292.9 MYX Mayne Pharma Ltd $ 4.950 -1.0% 405.4 ANN Ansell Limited $ 29.950 -1.1% 4,410.5 AFP Aft Pharmaceuticals $ 2.400 -1.2% 259.6 RGT Argent Biopharma Ltd $ 0.080 -1.2% 4.7 RAC Race Oncology Ltd $ 1.160 -1.3% 198.9 SNZ Summerset Grp Hldgs $ 10.300 -1.3% 2,513.8 HLS Healius $ 0.770 -1.9% 548.2 ALA Arovella Therapeutic $ 0.098 -2.0% 117.7 BMT Beamtree Holdings $ 0.245 -2.0% 72.6 ONE Oneview Healthcare $ 0.245 -2.0% 185.7 4DX 4Dmedical Limited $ 0.235 -2.1% 136.2 COV Cleo Diagnostics $ 0.380 -2.6% 48.8 RHT Resonance Health $ 0.038 -2.6% 17.5 AVH Avita Medical $ 1.670 -2.6% 217.6 SIG Sigma Health Ltd $ 2.890 -3.3% 32,726.4 PYC PYC Therapeutics $ 1.240 -4.2% 729.1 IXC Invex Ther $ 0.085 -4.5% 6.9 OIL Optiscan Imaging $ 0.105 -4.5% 87.7 ZLD Zelira Therapeutics $ 0.41 -6.8% 4.9 MDR Medadvisor Limited $ 0.075 -7.4% 43.8 BDX Bcaldiagnostics $ 0.058 -7.9% 20.5 GSS Genetic Signatures $ 0.330 -9.6% 76.1 CDX Cardiex Limited $ 0.036 -10.0% 18.7 PER Percheron $ 0.009 -10.0% 10.9 AGN Argenica $ 0.680 -10.5% 86.1 OSL Oncosil Medical $ 1.070 -10.8% 20.2 ECS ECS Botanics Holding $ 0.008 -11.1% 11.0 PEB Pacific Edge $ 0.085 -11.5% 75.9 IVX Invion Ltd $ 0.096 -12.7% 8.2 EZZ EZZ Life Science $ 2.030 -13.2% 99.1 TLX Telix Pharmaceutical $ 21.050 -13.8% 6,991.3 AVR Anteris Technologies $ 5.130 -16.4% 179.8 DXB Dimerix Ltd $ 0.470 -18.3% 285.1 SHG Singular Health $ 0.300 -18.9% 93.5 IMR Imricor Med Sys $ 1.225 -19.4% 324.2 MEM Memphasys Ltd $ 0.004 -20.0% 7.9 PCK Painchek Ltd $ 0.035 -22.2% 66.3 CHM Chimeric Therapeutic $ 0.003 -25.0% 11.4 VHL Vitasora Health Ltd $ 0.03 -28.2% 46.4 UCM Uscom Limited $ 0.01 -31.3% 2.9 UBI Universal Biosensors $ 0.02 -31.4% 7.2 IMU Imugene Limited $ 0.270 -38.9% 77.2 BOT Botanix Pharma Ltd $ 0.150 -53.1% 289.3 Patrys (ASX:PAB) rose ~182% in July after announcing a solid June quarter including a board restructure, $300,000 capital raise and actively pursuing partnering and licensing opportunities for both of its oncological cell therapy deoxymab assets. In July Patrys also announced a fully underwritten, pro-rata non-renounceable entitlement offer of three fully paid ordinary shares for every four shares held at an issue price of $0.001 per Share, together with on free-attaching new share for every four shares applied for and issued, to raise up to ~$1.78m. Lumos Diagnostics (ASX:LDX) rose more than 170% in July after l anding a landmark six-year distributor deal worth hundreds of millions of dollars to sell its rapid point-of-care diagnostic FebriDx in the US market. The FebriDx product is a simple test able to differentiate between bacterial and non-bacterial acute respiratory infections. The lucrative US licensing deal with Hong-Kong based PHASE Scientific could see Lumos net up to to US$317m (~A$487m), and has been described as one of the largest distribution deals of its type to be done by an ASX-listed point-of-care diagnostics company. Adelaide-based Clever Culture Systems (ASX:CC5), rose 81.3% in July after announcing global pharmaceutical giant Novo Nordisk had purchased one of its flagship APAS Independence instruments for evaluation. The machine will be delivered to Novo's central team in Denmark, where it will undergo a full-scale evaluation to assess its suitability for deployment across Novo's global manufacturing network. The APAS Independence uses AI technology to automate one of the most time-consuming parts of microbiology, analysing agar plates for contamination. Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) was up 74.8% in July after completing a large $203m institutional placement at a 15% premium to the company's 15-day average price, to fund their clinical program. Executive chairman Dr Alan Taylor told Stockhead the 'fast, well executed and sizeable' placement was to a small group of local institutional investors "close to the company". 'I have never done a deal that fast,' Taylor said. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group .' At Stockhead, we tell it like it is. While Lumos Diagnostics and Clever Culture Systems are Stockhead advertisers, the companies did not sponsor this article. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.

NRL must act as expansion team faces impending doom
NRL must act as expansion team faces impending doom

News.com.au

time40 minutes ago

  • News.com.au

NRL must act as expansion team faces impending doom

The champagne has barely had time to go flat since the Bears were triumphantly reinstated and it already looks like they'll need to merge with Manly again. Yes, it's been a glorious honeymoon for the black-and-red diehards since the Perth franchise was welcomed as the NRL's newest entity. But sadly all the talk of dream signings and fantasy XIII's have now been swamped with the jarring realisation that assembling an actual NRL squad within 18 months might be a bigger b*stard than first expected. Even though the club can't approach any contracted players until after November 1st, already there are massive concerns piling up about the monstrous task ahead. Let's remember this is a franchise building from a standing start with nothing more than a history, a logo and a Florimo. Plus there's the stress of launching the project against a timeframe that's like packing a scrum with a five second shot clock and six wingers. Further to that, they're humbly entering an AFL stronghold policed by Kerry Stokes' media monopoly, meaning they'll cop stones from the moment they disembark the plane let alone if they start the season like a cold Toyota Cressida. But of greatest concern is the squad building exercise, mainly because the Bears will be fishing in a parched player market of catfish, dregs and expensive teases. Add the Papua New Guinea franchise soon to be feeding from the same pool, and coach Mal Meninga's biggest issue could be getting himself fit enough again to play in the centres. Sure, nobody claimed it would be a cinch convincing 30 blokes to relocate across the country to a timezone closer to Jakarta than Sydney. But the challenges were never a secret, and that's why there's one major stakeholder in this arrangement that's dropped its lollies. Peter V'landys and the ARLC should be fiercely applauded for reintroducing the Bears back to rugby league and for gifting Western Australia the team it deserves. But after months of subluxing their shoulders patting themselves on the back, it's time they threw genuine support behind the new licence that isn't just standing at press conferences throwing shade at the AFL. As we know, the PNG licence will be reportedly armed with a festoon of salary cap exemptions relating to tax free salaries and relocation costs, whereas the only exemption the Bears have thus far is from good players and hope. If V'Landys is serious about the Perth club being 'competitive in the first year' then he needs to wake up and afford the Bears the same licence to spend with abandon. And if he doesn't, the club is doomed before it even starts. Without help, the Bears franchise will serve its formative years abused by AFL narks and sneaky player agents bumping up their client's asking price. Already we've seen blue chip prospects dropping off by the day for the fledging franchise, with Kalyn Ponga, Jahrome Hughes and Api Koroisau the latest ruled out after restating their commitment to Eastern Standard Time. This has left so little to get excited about that attention has turned to star targets in Cameron Munster and Tino Fa'asuamaleaui even though both are contracted for 2027. Undoubtedly these blokes are needle-moving names who'd cost the farm for any club. But with the mooted Bear Tax applied to their already-exorbitant asking price, their cost to relocate West is already being speculated to cost upwards of $2m a season. And while we'd all love a Tino in the middle or a Munny on a 10 hour round trip flight once a fortnight, if the Bears are forced to stump up the figures discussed within the NRL's current salary cap of $11.8m they'll barely have enough left over for a bench. Here's where the NRL needs to stop being a tightarse by padding out the Bears salary cap with more support and extra zeros. Allow the Perth club 15% on top of the agreed figure and bolster this with some kinda special access to local juniors, ie Penrith's. Then pick up the bill for any relocation costs and flak jackets required when the squad is first smuggled in to town past Perth's Channel Seven bureau. Then to keep these far-flung heroes happy despite being five hours away surrounded by West Coast Eagles fans and bikies, the NRL needs to legislate the Bears access to ceiling-free third party agreements. As we know, statistics allege that Perth's population currently stands at 87% mining magnates. And while many have their revenue tied up in AFL, it means with some gentle convincing there could be an NRL franchise backed by the most powerful person in Australia, and it wouldn't be PNG and Anthony Albanese. With help from the NRL, the Bears could jump in bed with Gina Rinehart and access that sweet mining cabbage so they can fish in the player market with dynamite.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store